Intravenous immunoglobulin for infectious diseases: back to the pre-antibiotic and passive prophylaxis era?
The dramatic increase in both the number of novel infectious agents and resistance to antimicrobial drugs has incited the need for adjunct therapies in the war against infectious diseases. Exciting recent studies have demonstrated the use of antibodies in the form of intravenous immunoglobulin (IVIg) against infections. By virtue of the diverse repertoire of immunoglobulins that possess a wide spectrum of antibacterial and antiviral specificities, IVIg provides antimicrobial efficacy independently of pathogen resistance and represents a promising alternative strategy for the treatment of diseases for which a specific therapy is not yet available.
Bayry
Jagadeesh
J
INSERM U430 and Université Pierre et Marie Curie, Institut des Cordeliers, 15 rue de l'Ecole de Médecine, 75006, Paris, France.
Lacroix-Desmazes
Sébastien
S
Kazatchkine
Michel D
MD
Kaveri
Srini V
SV
D000818:Animals; D001424:Bacterial Infections / Q000628:therapy; D006801:Humans; D007116:Immunization, Passive; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007239:Infections / Q000628:therapy*; D014777:Virus Diseases / Q000628:therapy
D016756:Immunoglobulins, Intravenous